← boardnext 2028-01next 2029-03-31
CELC
Celcuity Incdistress 3/10 · well-funded / low risk$89.15-1%today-39% from 52w high
Lead: Male
Revenue
pre-revenue
Liquidity
$387M
Runway
2.2 yrs
Shares 1y
+15%
Price & events
-19.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
+1.0%
1W
-1.2%
1M
-21.5%
3M
-19.0%
6M
+534.5%
1Y
+384.2%
2Y
+318.5%
5Y
+754.7%
All
Overview
- Market Cap
- $4.35B
- Enterprise Value
- $4.34B
- Volume
- 91.66K
- 52 Week Range
- $13.54 – $145
- Total Shares
- 48.77M
- Float Shares
- 29.91M
- Short %
- 33.80%
- % Held by Insiders
- 10.03%
- % Held by Institutions
- 101.79%
- RVOL
- 0.06x
- Beta
- 0.16
Pipeline stages · 2 programs
Gedatolisib, Darolutamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Arm A: Gedatolisib, Palbociclib, Fulvestrant
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 1/2 | Gedatolisib, Darolutamidebreakthroughfast trackpriority review | mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease, Prostatic Neoplasms, Castration-Resistant, Prostate Cancer | — | recruiting |
| 2029-03-31 Estimated 50% readout ~2029-06-14 | Phase 3 | Arm A: Gedatolisib, Palbociclib, Fulvestrant | Breast Cancer | — | recruiting |
Catalyst news & presentations · 3
- Q3 2026regulatory submissionFiled (NDA/BLA)REVTORPYK (gedatolisib) · Plan to submit sNDA for PIK3CA mutated cohort based on Phase 3 VIKTORIA-1 trial.SEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- 2025-10-18rolling reviewgedatolisib · Rolling NDA submission initiated with FDA Real-Time Oncology Review program.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $163 (+83% upside) · 11 analysts
- 2026-07-15HC Wainwright & Co.Buy
- 2026-07-15CitizensMarket Outperform
- 2026-06-03Craig-HallumBuy
- 2026-06-03HC Wainwright & Co.Buy
- 2026-06-03Wells FargoOverweight
- 2026-05-18HC Wainwright & Co.Buy
Competitors — Male
Recent news
- 2026-07-23Bronstein, Gewirtz & Grossman, LLC Is Investigating Celcuity Inc. (CELC) And Encourages Stockholders to Connect - ACCESS Newswire
- 2026-07-22With FDA approval, Celcuity sees big future for its new breast cancer drug - Star Tribune
- 2026-07-22CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits
- 2026-07-21CELCUITY ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
- 2026-07-21Why CELC Stock Declined 15% in a Week Despite a Major FDA Win - TradingView
- 2026-07-21Celcuity falls as rollout concerns overshadow FDA approval of breast cancer drug - MSN
- 2026-07-21Kirby McInerney LLP investigates Celcuity for p... - Pluang
- 2026-07-21CELC INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.